SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that John Finn, Ph.D., Chief Scientific Officer at Trius Therapeutics, will present “Innovative Antibacterial Drugs by Design; The Trius Therapeutics Story” at the San Diego Biotechnology Network event taking place on October 26, 2010 from 5:30-9:30 p.m. PT.
More information on the event is available at http://sdbn.org/october.
About Trius Therapeutics
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company’s lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company’s torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.
SOURCE Trius Therapeutics, Inc.
